[논문]Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus

Zivcec, Marko; Guerrero, Lisa I.W.; Albariñ; o, Cé; sar G.; Bergeron, É; ric; Nichol, Stuart T.; Spiropoulou, Christina F.

doi:10.1016/j.antiviral.2017.08.014

Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus 원문보기

Antiviral research, v.146, 2017년, pp.112 - 120

Zivcec, Marko (Corresponding author.) , Guerrero, Lisa I.W. , Albariño, César G. , Bergeron, Éric , Nichol, Stuart T. , Spiropoulou, Christina F.

Abstract ▼ AI-Helper

Abstract Despite the serious public health impact of Crimean-Congo hemorrhagic fever (CCHF), the efficacy of antivirals targeting the causative agent, CCHF virus (CCHFV), remains debatable. Neutralizing monoclonal antibodies (MAbs) targeting the CCHFV glycoprotein Gc have been reported to protect mice against challenge with the prototype CCHFV strain, IbAr10200. However, due to extensive sequence diversity of CCHFV glycoproteins, it is unknown whether these MAbs neutralize other CCHFV strains. We initially used a CCHF virus-like particle (VLP) system to generate 11 VLP moieties, each possessing a glycoprotein from a genetically diverse CCHFV strain isolated in either Africa, Asia, the Middle East, or southeastern Europe. We used these VLPs in biosafety level 2 conditions to efficiently screen MAb cross-neutralization potency. Of the 16 MAbs tested, 3 (8A1, 11E7, and 30F7) demonstrated cross-neutralization activity with most CCHF VLPs, with 8A1 neutralizing all VLPs tested. Although binding studies suggest that none of the MAbs compete for the same epitope, combining 11E7, 30F7, or both 11E7 and 30F7 with 8A1 had no additive effect on increasing neutralization in this system. To confirm our findings from the VLP system, the 3 MAbs capable of strain cross-neutralization were confirmed to effectively neutralize 5 diverse CCHFV strains in vitro. Passaging CCHFV strains in the presence of sub-neutralizing concentrations of MAbs did not generate escape mutants resistant to subsequent neutralization. This study demonstrates the utility of the VLP system for screening neutralizing MAbs against multiple CCHFV strains, and provides the first evidence that a single MAb can effectively neutralize a number of diverse CCHFV strains in vitro, which may lead to development of future CCHF therapeutics. Highlights Analyzed a panel of CCHFV targeting monoclonal antibodies (MAbs) to broadly neutralize CCHFV particles. A virus-like particle (VLP) neutralization assay identified 3 MAbs capable of neutralizing >8 VLP moieties. MAbs do not compete for the same epitopes and may be used in a combination. The neutralizing potency of MAbs confirmed with a panel of diverse infectious CCHFV. No escape mutants were detected following serial passaging.

주제어

참고문헌 (31)

Antivir. Res. Bente 100 159 2013 10.1016/j.antiviral.2013.07.006 Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity

상세보기
PLoS Pathog. Bergeron 11 e1004879 2015 10.1371/journal.ppat.1004879 Recovery of recombinant Crimean Congo hemorrhagic fever virus reveals a function for non-structural glycoproteins cleavage by furin

상세보기
J. Virol. Bertolotti-Ciarlet 79 6152 2005 10.1128/JVI.79.10.6152-6161.2005 Cellular localization and antigenic characterization of Crimean-Congo hemorrhagic fever virus glycoproteins

상세보기
PLoS One Buttigieg 9 2014 10.1371/journal.pone.0091516 A novel vaccine against Crimean-Congo haemorrhagic fever protects 100% of animals against lethal challenge in a mouse model

상세보기
PLoS Negl. Trop. Dis. Canakoglu 1 2015 Immunization of knock-out α/β interferon receptor mice against high lethal dose of Crimean-Congo hemorrhagic fever virus with a cell culture based vaccine
Antivir. Res. Cross 133 218 2016 10.1016/j.antiviral.2016.08.012 Treatment of Lassa virus infection in outbred Guinea pigs with first-in-class human monoclonal antibodies

상세보기
PLoS One Dowall 11 1 2016 10.1371/journal.pone.0156637 Protective effects of a modified Vaccinia Ankara-based vaccine candidate against Crimean-Congo Haemorrhagic Fever virus require both cellular and humoral responses

상세보기
Vector Borne Zoonotic Dis. Duygu 12 812 2012 10.1089/vbz.2011.0694 Re-evaluation of 400 Crimean-Congo hemorrhagic fever cases in an endemic area: is ribavirin treatment suitable?

상세보기
Curr. Opin. Virol. Ergonul 2 215 2012 10.1016/j.coviro.2012.03.001 Crimean-Congo hemorrhagic fever virus: new outbreaks, new discoveries

상세보기
Virology Erickson 361 348 2007 10.1016/j.virol.2006.11.023 N-linked glycosylation of Gn (but not Gc) is important for Crimean Congo hemorrhagic fever virus glycoprotein localization and transport

상세보기
PLoS One Estrada-Peña 10 1 2015 10.1371/journal.pone.0125760 The impact of climate trends on a tick affecting public health: a retrospective modeling approach for Hyalomma marginatum (ixodidae)

상세보기
Cell Flyak 164 392 2016 10.1016/j.cell.2015.12.022 Cross-reactive and potent neutralizing antibody responses in human survivors of natural Ebolavirus infection

상세보기
Vector Borne Zoonotic Dis. Gargili 11 747 2011 10.1089/vbz.2010.0030 Crimean-Congo hemorrhagic fever in European part of Turkey: genetic analysis of the virus strains from ticks and a seroepidemiological study in humans

상세보기
Sci. Transl. Med. Geisbert 6 2014 10.1126/scitranslmed.3008929 Therapeutic treatment of nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody

상세보기
Epidemiol. Infect. Goedhals 142 1952 2014 10.1017/S0950268814000818 Next-generation sequencing of southern African Crimean-Congo haemorrhagic fever virus isolates reveals a high frequency of M segment reassortment

상세보기
J. Virol. Hinkula 2017 10.1128/JVI.02076-16 Immunization with DNA plasmids coding for Crimean-Congo hemorrhagic fever virus capsid and envelope proteins and/or virus-like particles induces protection and survival in challenged mice

상세보기
J. Clin. Virol. Koksal 47 65 2010 10.1016/j.jcv.2009.11.007 The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey

상세보기
Vector-Borne Zoonotic Dis. Kortekaas 15 759 2015 10.1089/vbz.2015.1855 Crimean-Congo hemorrhagic fever virus subunit vaccines induce high levels of neutralizing antibodies but no protection in STAT1 knockout mice

상세보기
Jpn. J. Infect. Dis. Kubar 64 439 2011 10.7883/yoken.64.439 Prompt administration of Crimean-Congo hemorrhagic fever ( CCHF ) virus hyperimmunoglobulin in patients diagnosed with CCHF and viral load monitorization by Reverse Transcriptase-PCR

상세보기
PLoS Pathog. Pal 9 2013 10.1371/journal.ppat.1003312 Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus

상세보기
Emerg. Infect. Dis. Papa 20 288 2014 10.3201/eid2002.130690 Crimean-Congo hemorrhagic fever virus, Greece

상세보기
J. Med. Virol. Papa 88 21 2016 10.1002/jmv.24312 Cytokines as biomarkers of Crimean-Congo hemorrhagic fever

상세보기
PLoS Negl. Trop. Dis. Qiu 6 31 2012 10.1371/journal.pntd.0001575 Ebola GP-specific monoclonal antibodies protect mice and Guinea pigs from lethal Ebola virus infection

상세보기
Nature Qiu 514 47 2014 10.1038/nature13777 Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp

상세보기
BMC Infect. Dis. Soares-Weiser 10 207 2010 10.1186/1471-2334-10-207 Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis

상세보기
J. Infect. Dis. Spengler 2017 10.1093/infdis/jix215 Crimean-Congo hemorrhagic fever in humanized mice reveals Glial cells as primary targets of neurological infection

상세보기
South Afr. Med. J. Van Eeden 68 718 1985 A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital Part II. Management of patients
Science Wec 354 12598 2016 10.1126/science.aag3267 A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses

상세보기
Curr. Top. Microbiol. Immunol. Wu 317 103 2008 Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab

상세보기
Proc. Natl. Acad. Sci. U. S. A. Zeitlin 113 4458 2016 10.1073/pnas.1600996113 Monoclonal antibody therapy for Junin virus infection

상세보기
PLoS Negl. Trop. Dis. Zivcec 9 2015 10.1371/journal.pntd.0004259 Assessment of inhibitors of pathogenic Crimean-Congo hemorrhagic fever virus strains using virus-like particles

상세보기

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (31)

이 논문을 인용한 문헌

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트